Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26115 | 0.73 | — | — | |
| SCHEMBL341533 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL503226 | 0.72 | ALDH1A1 (0.47) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL184471 | 0.71 | ACHE (0.50) | ALDH1A1TSHRACHETDP1 | |
| SCHEMBL3834701 | 0.70 | ALDH1A1 (0.60) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL1304637 | 0.69 | ALDH1A1 (0.37) | ALDH1A1ACHECYP3A4TDP1 | |
| SCHEMBL2229713 | 0.69 | ALDH1A1 (0.44) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL8373256 | 0.69 | ALDH1A1 (0.44) | ALDH1A1TSHRACHETPMTPRSS1 | |
| SCHEMBL20750027 | 0.69 | ALDH1A1 (0.38) | ALDH1A1TSHRACHETPMTCYP3A4 | |
| SCHEMBL23202757 | 0.69 | ALDH1A1 (0.61) | ALDH1A1TSHRACHETPMTPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750896-B1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | TAKASAGO PERFUMERY CO LTD (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-3750896-A1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | Takasago International Corporation (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369700-A1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-11-26 | — | — | US | disclosed |
| US-9238667-B2 | Rhodium catalyst and method for producing amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | SPERA PHARMA, INC. (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2832738-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832738-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | SPERA PHARMA, INC. (JP) | 2010-05-20 | — | — | US | disclosed |
| US-7678942-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-1452537-B1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | H1-10, ITPA, RER1 | ALDH1A1 4580/4885TSHR 1063/4885ACHE 1352/4885 |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | ALDH1A1 2206/4885TSHR 1972/4885ACHE 7/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | ALDH1A1 4580/4885TSHR 1089/4885ACHE 1361/4885 |
| US-20200369700-A1 | CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND | GPR39, GNG2, AGL | ALDH1A1 2790/4885TSHR 339/4885ACHE 2101/4885 |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | PRMT7, PRMT5, HNMT | ALDH1A1 2581/4885TSHR 846/4885ACHE 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.